HK Stock Market Move | XUANZHUBIO-B(02575) Rises Over 5% in Early Trading as New Indication for Pyrrolitinib Is Included in the National Basic Medical Insurance Drug Catalog

date
09:34 16/11/2026
avatar
GMT Eight
XUANZHUBIO-B (02575) rose over 5% in early trading. As of press time, it was up 4.96% at HK$8.675, with a turnover of HK$3.1644 million.
XUANZHUBIO-B(02575) rose over 5% in early trading, up 4.96% as of press time at HK$8.675, with turnover of HK$3.1644 million. On the news front, on November 15, XUANZHUBIO-B announced that the new indication for its self-developed innovative drug Pyrrolitinib Tablets, in combination with an aromatase inhibitor (AI) for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer patients, has been included in the "National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog (2026)." The 2026 National Basic Medical Insurance Drug Catalog will officially take effect on January 1, 2027. As of the date of this announcement, all three indications approved for Pyrrolitinib in mainland China have been included in the National Basic Medical Insurance Drug Catalog. The board believes that this inclusion will further expand the potential patient population that can benefit from Pyrrolitinib Tablets, help accelerate its hospital access and clinical application, thereby promoting the commercialization process of Pyrrolitinib Tablets and further consolidating the Group's competitive advantage in the HR+/HER2- advanced breast cancer treatment field.